Market Overview

Emerald Health Therapeutics Engages Acorn Management Partners for Investor Relations

Share:

VICTORIA, British Columbia, Aug. 24, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH, OTCQX:EMHTF) ("Emerald") today announced that it has engaged Acorn Management Partners, an Atlanta-based investor relations firm, to provide investor relations and communications services to the company, subject to TSX Venture Exchange acceptance.

Acorn has been engaged for a one year term expiring July 29, 2019, and will be entitled to receive a monthly fee of $8,500 (U.S.). The agreement will automatically renew on a quarterly basis during the term and may be terminated by the company upon 30 days notice prior to the end of each quarter.

Acorn currently has no direct or indirect interest in the securities of the company, or any right or intent to acquire such an interest.

The appointment of Acorn as an investor relations consultant of the company remains subject to regulatory acceptance of applicable filings with the TSX Venture Exchange.

About Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics (TSXV:EMH, OTCQX:EMHTF, Frankfurt: TBD)) is licensed in Canada to produce and sell dried cannabis and cannabis oil for medical purposes. Emerald owns 50% of Pure Sunfarms, which is converting a licensed existing 1.1 million square foot greenhouse in Delta, BC and is now in commercial production. It owns Agro-Biotech, a Québec-based licensed cannabis grower with a 75,000 square foot indoor facility and is planning to add a 500,000 square foot greenhouse in Metro Vancouver. Emerald's team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing value-added cannabis-based products with potential wellness and medical benefits. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical, and nutraceutical products that may provide wellness and medical benefits by interacting with the human body's endocannabinoid system.

Please visit www.emeraldhealth.ca for more information or contact:
Rob Hill, Chief Financial Officer
(800) 757 3536 Ext. #5

Ray Lagace, Investor Relations Manager
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Primary Logo

View Comments and Join the Discussion!